Brief: Immunocore Presents New Data From Its Phase 2 Clinical Trial Of Tebentafusp At The ESMO Congress 2021

Immunocore Holdings

20/09/2021 12:51

Sept 20 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE PRESENTS DATA AT THE EUROPEAN SOCIETY FOR
MEDICAL
ONCOLOGY (ESMO) CONGRESS 2021 DEMONSTRATING A REDUCTION IN
CIRCULATING TUMOR DNA (CTDNA) WHILE ON TEBENTAFUSP IS ASSOCIATED
WITH OVERALL SURVIVAL IN THE PHASE 2 CLINICAL TRIAL
    * IMMUNOCORE HOLDINGS PLC - LINEAR CORRELATION BETWEEN
MAGNITUDE
OF CTDNA REDUCTION ON TEBENTAFUSP AND IMPROVED OVERALL SURVIVAL
    * IMMUNOCORE HOLDINGS PLC - 70% OF EVALUABLE PATIENTS HAD
ANY
CTDNA REDUCTION AND 14% HAD CTDNA CLEARANCE

Source text for Eikon:  ID:nGNX40pJrL 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))